EXE vs. DNTL, SIA, WELL, DR, KDA, NLH, PHA, BLU, TRIL, and TLRY
Should you be buying Extendicare stock or one of its competitors? The main competitors of Extendicare include dentalcorp (DNTL), Sienna Senior Living (SIA), WELL Health Technologies (WELL), Medical Facilities (DR), KDA Group (KDA), Nova Leap Health (NLH), Premier Health of America (PHA), BELLUS Health (BLU), Trillium Therapeutics (TRIL), and Tilray Brands (TLRY). These companies are all part of the "medical" sector.
Extendicare (TSE:EXE) and dentalcorp (TSE:DNTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.
In the previous week, dentalcorp had 1 more articles in the media than Extendicare. MarketBeat recorded 1 mentions for dentalcorp and 0 mentions for Extendicare. Extendicare's average media sentiment score of 0.00 equaled dentalcorp'saverage media sentiment score.
Extendicare received 125 more outperform votes than dentalcorp when rated by MarketBeat users. However, 63.41% of users gave dentalcorp an outperform vote while only 48.87% of users gave Extendicare an outperform vote.
20.2% of Extendicare shares are held by institutional investors. Comparatively, 51.3% of dentalcorp shares are held by institutional investors. 13.9% of Extendicare shares are held by insiders. Comparatively, 0.2% of dentalcorp shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Extendicare has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, dentalcorp has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
Extendicare has higher earnings, but lower revenue than dentalcorp. dentalcorp is trading at a lower price-to-earnings ratio than Extendicare, indicating that it is currently the more affordable of the two stocks.
Extendicare has a net margin of 2.63% compared to dentalcorp's net margin of -4.44%. Extendicare's return on equity of 37.03% beat dentalcorp's return on equity.
Extendicare currently has a consensus target price of C$8.33, indicating a potential upside of 10.82%. dentalcorp has a consensus target price of C$10.03, indicating a potential upside of 28.56%. Given dentalcorp's stronger consensus rating and higher possible upside, analysts clearly believe dentalcorp is more favorable than Extendicare.
Summary
dentalcorp beats Extendicare on 9 of the 17 factors compared between the two stocks.
Get Extendicare News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Extendicare Competitors List
Related Companies and Tools
